Home・Stock List・Xenon Pharmaceuticals Inc

Xenon Pharmaceuticals Inc

Closed

SectorHealthcare

63.11 -1.62

Buy Sell

Overview

Share price change

24h

Current

Min

62.74

Max

64.15

Key metrics
By Trading Economics
Income	3M -102M
EPS	-1.17
Employees	358
EBITDA	-7.6M -112M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+23.11% upside

Dividends
By Acuity
Next Earnings	2 Nov 2026

Market Stats
By TradingEconomics
Market Cap	471M 6B
Previous open	64.73
Previous close	63.11

Xenon Pharmaceuticals Inc Chart

Past performance is not a reliable indicator of future results.

Related News

10 Aug 2026, 23:41 UTC

Xenon Pharmaceuticals Inc shares are higher in after-market hours, despite earlier pulling back from a session high. No specific news was identified for the movement.

7 Aug 2026, 20:06 UTC

News

Social Media

Xenon Pharmaceuticals shares are lower as RBC cuts the price target to $81.00 and the company reports a larger-than-expected Q2 loss of $110.7 million.

6 Aug 2026, 19:36 UTC

Xenon Pharmaceuticals Inc. shares are lower today, retracing earlier gains. The stock is trading near the lower end of its one-month range.

5 Aug 2026, 23:41 UTC

Xenon Pharmaceuticals Inc. shares are higher in after-market hours amid notable volatility, though no specific news was identified to explain the movement.

4 Aug 2026, 21:02 UTC

Xenon Pharmaceuticals Inc. shares are trading lower during after-market hours, breaking a recent trend of higher daily closes since Tuesday.

3 Aug 2026, 19:46 UTC

News

Xenon Pharmaceuticals announced equity inducement grants totaling 32,758 share options and 19,013 RSUs. Shares are lower during Monday's session, near the one-month range's low.

31 Jul 2026, 23:01 UTC

News

Xenon Pharmaceuticals shares are lower in after-market hours following the announcement of inducement grants for eleven new non-officer employees.

30 Jul 2026, 13:36 UTC

Xenon Pharmaceuticals Inc shares are higher in pre-market trading, reflecting a broader market recovery despite rising treasury yields and geopolitical tensions.

29 Jul 2026, 21:02 UTC

Xenon Pharmaceuticals Inc. shares are little changed after-market, continuing a trend of three consecutive lower daily finishes amid a broader decline in U.S. equities.

28 Jul 2026, 19:16 UTC

Xenon Pharmaceuticals Inc shares are lower today, pulling back from earlier gains amid notable volatility and no specific news to explain the movement.

27 Jul 2026, 16:06 UTC

Xenon Pharmaceuticals Inc shares are lower today amid a broader market decline linked to falling crude oil prices and eased geopolitical tensions.

24 Jul 2026, 23:31 UTC

Xenon Pharmaceuticals Inc shares are higher in after-market trading, reflecting positive momentum since Friday's close, despite no specific news identified.

23 Jul 2026, 23:51 UTC

Xenon Pharmaceuticals Inc shares are lower in after-market hours, continuing a downward trend with no specific news identified to explain the decline.

22 Jul 2026, 23:11 UTC

Xenon Pharmaceuticals Inc shares declined in after-market trading amid broader market volatility, influenced by geopolitical tensions and rising crude oil prices.

21 Jul 2026, 19:36 UTC

Xenon Pharmaceuticals shares are higher, supported by overall market strength and advances in biotechnology stocks, despite no specific company news identified.

20 Jul 2026, 22:02 UTC

Xenon Pharmaceuticals Inc. shares are lower in after-market trading, following notable volatility and no specific news identified. The stock remains above its 20-day moving average.

Peer Comparison

Price change

Xenon Pharmaceuticals Inc Forecast

Price Target

By TipRanks

23.11% upside

12 Months Forecast

Average 78 USD 23.11%

High 90 USD

Low 63 USD

Based on 12 Wall Street analysts offering 12 month price targets forXenon Pharmaceuticals Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

12 ratings

Buy

Hold

Sell

Based on 12 analysts giving stock ratings to Xenon Pharmaceuticals Inc - Dist in the past 3 months.

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Xenon Pharmaceuticals Inc

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.